Determinants for Acceptance of COVID-19 Vaccine in Nigeria.
acceptance
adults
covid-19
determinants
nigeria
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
accepted:
22
11
2021
entrez:
29
12
2021
pubmed:
30
12
2021
medline:
30
12
2021
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic heralded an unprecedented race to the development of several vaccine candidates at record speeds never seen in global health. Within nine months, Pfizer-BioNTech's COVID-19 vaccine was approved by the United States FDA. Unfortunately, while these advances were ongoing, there was a burgeoning epidemic of disinformation about the virus and the vaccines that affected the willingness of people, especially minority groups, to get vaccinated. In Nigeria, this wave of vaccine hesitancy was happening against the backdrop of landmark pharmaceutical litigations such as the 2007 Pfizer trovafloxacin lawsuit in the country. To assess the determinants of the COVID-19 vaccine's acceptability among Nigerians. Following ethical approval, a population-based cross-sectional study was conducted from November 2020 to January 2021 using an adapted pretested, self-administered questionnaire originally designed by Amyn Malik and colleagues who conducted a similar study at Yale University School of Public Health. The participants were recruited through simple random sampling using a list of community and corporate sites obtained from Google Maps in the three regional zones of Nigeria (north, east, and west) in diverse occupational and residential settings. Information obtained includes socio-demographics, medical history related to COVID-19, level of knowledge, risk perception, and attitudes toward COVID-19 and the vaccines. Descriptive and inferential statistics were done, and results were summarized into percentages and associations. The level of statistical significance was set at a p-value of <0.05. Using the open EpiR package (Emory), we determined a minimum of 340 participants for a statistical power of 80%. A total of 358 responses were obtained out of the 120 questionnaires distributed in each of the three regions, of which 189 (53%) were females. The mean age of respondents was 32 years (±11.2 SD). About 75% of the participants had at least a college education. The majority (66.2%) of the participants were willing to accept the approved vaccine. The mean risk perception score for COVID-19 was 5.1 (±2.2 SD) out of 10, while the mean COVID-19 symptom knowledge score was 8.6 (±4.1 SD) out of 19. Variables such as being male, identifying as Christian, Hausa ethnicity, and living in northern Nigeria had a statistically significant relationship with the willingness to get vaccinated. Over 60% of Nigerians are willing to take the COVID-19 vaccines if recommended by health workers. We found male gender, religion, ethnicity, and geographical location to positively influence the willingness of Nigerians to get vaccinated against COVID-19. Health workers should be supported to go beyond the confines of the hospital to educate the general public in schools, marketplaces, churches, and corporate organizations on the efficacy and safety of the approved vaccines.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic heralded an unprecedented race to the development of several vaccine candidates at record speeds never seen in global health. Within nine months, Pfizer-BioNTech's COVID-19 vaccine was approved by the United States FDA. Unfortunately, while these advances were ongoing, there was a burgeoning epidemic of disinformation about the virus and the vaccines that affected the willingness of people, especially minority groups, to get vaccinated. In Nigeria, this wave of vaccine hesitancy was happening against the backdrop of landmark pharmaceutical litigations such as the 2007 Pfizer trovafloxacin lawsuit in the country.
AIM
OBJECTIVE
To assess the determinants of the COVID-19 vaccine's acceptability among Nigerians.
MATERIALS AND METHODS
METHODS
Following ethical approval, a population-based cross-sectional study was conducted from November 2020 to January 2021 using an adapted pretested, self-administered questionnaire originally designed by Amyn Malik and colleagues who conducted a similar study at Yale University School of Public Health. The participants were recruited through simple random sampling using a list of community and corporate sites obtained from Google Maps in the three regional zones of Nigeria (north, east, and west) in diverse occupational and residential settings. Information obtained includes socio-demographics, medical history related to COVID-19, level of knowledge, risk perception, and attitudes toward COVID-19 and the vaccines. Descriptive and inferential statistics were done, and results were summarized into percentages and associations. The level of statistical significance was set at a p-value of <0.05. Using the open EpiR package (Emory), we determined a minimum of 340 participants for a statistical power of 80%.
RESULTS
RESULTS
A total of 358 responses were obtained out of the 120 questionnaires distributed in each of the three regions, of which 189 (53%) were females. The mean age of respondents was 32 years (±11.2 SD). About 75% of the participants had at least a college education. The majority (66.2%) of the participants were willing to accept the approved vaccine. The mean risk perception score for COVID-19 was 5.1 (±2.2 SD) out of 10, while the mean COVID-19 symptom knowledge score was 8.6 (±4.1 SD) out of 19. Variables such as being male, identifying as Christian, Hausa ethnicity, and living in northern Nigeria had a statistically significant relationship with the willingness to get vaccinated.
CONCLUSION
CONCLUSIONS
Over 60% of Nigerians are willing to take the COVID-19 vaccines if recommended by health workers. We found male gender, religion, ethnicity, and geographical location to positively influence the willingness of Nigerians to get vaccinated against COVID-19. Health workers should be supported to go beyond the confines of the hospital to educate the general public in schools, marketplaces, churches, and corporate organizations on the efficacy and safety of the approved vaccines.
Identifiants
pubmed: 34963828
doi: 10.7759/cureus.19801
pmc: PMC8695669
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e19801Informations de copyright
Copyright © 2021, Eze et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Vaccine. 2012 Feb 8;30(7):1255-64
pubmed: 22214889
Lancet Glob Health. 2020 Jun;8(6):e790-e798
pubmed: 32573443
EClinicalMedicine. 2020 Sep;26:100495
pubmed: 32838242
Int J Nurs Stud. 2021 Feb;114:103854
pubmed: 33326864
J Community Health. 2020 Oct;45(5):881-890
pubmed: 32318986
Lancet. 2020 Nov 21;396(10263):1614-1616
pubmed: 33159850
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
Vaccine. 2009 Jun 19;27(30):4018-24
pubmed: 19389442
Pan Afr Med J. 2020 May 06;35(Suppl 2):24
pubmed: 33623549
Lancet. 2010 Mar 20;375(9719):970-1
pubmed: 20333812
Biosaf Health. 2021 Feb;3(1):4-7
pubmed: 32935084
Aliment Pharmacol Ther. 2020 Jun;51(12):1438-1439
pubmed: 32352178
BMJ Open. 2017 Mar 10;7(3):e013853
pubmed: 28283489
Lancet Infect Dis. 2020 Jul;20(7):769-770
pubmed: 32445713